Utah Governor and BioUtah Recognize Co-Diagnostics Following Saudi Arabia Joint Venture
Co-Diagnostics' expansion into Saudi Arabia through a new joint venture demonstrates Utah's growing influence in global life sciences and represents significant international market penetration for local diagnostic technology.
Utah Governor Spencer Cox joined BioUtah President and CEO Kelvyn Cullimore in recognizing Co-Diagnostics, Inc. for its recent formation of CoMira Diagnostics, a joint venture in the Kingdom of Saudi Arabia. The recognition highlights the growing international reach of Utah-based life sciences companies and their expanding global market presence.
Governor Cox emphasized the significance of this expansion, stating that Co-Diagnostics represents Utah-born companies competing internationally. Their expansion across the Middle East and North Africa regions demonstrates the strength of Utah's life sciences sector and the determination of local entrepreneurs. The governor expressed pride in seeing a Utah company developing diagnostic tools that benefit patients worldwide through their advanced molecular testing platform.
BioUtah's Cullimore noted that Co-Diagnostics' recent signing of a definitive joint venture agreement with a company in Saudi Arabia confirms the company's expanding leadership position in global diagnostics markets. As an Elite member of BioUtah, Co-Diagnostics represents the Utah life sciences community, which ranks among the fastest-growing sectors in the United States. The joint venture announcement follows Co-Diagnostics' established presence in molecular diagnostics development and manufacturing.
The company's proprietary technology platform enables the development of advanced molecular diagnostic tests designed to detect and analyze nucleic acid molecules, including DNA and RNA. This technology also supports the development of tests for the Co-Dx PCR at-home and point-of-care platform, though these applications remain subject to regulatory review and are not currently available for sale. The Saudi joint venture represents a strategic expansion into Middle Eastern markets, building on the company's existing diagnostic capabilities and international business development efforts.
This international expansion underscores the growing importance of Utah's life sciences industry as a driver of both economic growth and healthcare innovation. The recognition by state leadership and industry representatives highlights how local companies are leveraging specialized technological expertise to compete in global markets while advancing diagnostic capabilities that serve patients across international borders.